Pharmacokinetic-pharmacodynamic modeling of oral ranitidine: implications in efficacy and safety.
Franco
C
C
Glaxo-Wellcome México, México, D.F.
Flores-Murrieta
F J
FJ
Castañeda-Hernández
G
G
D000284:Administration, Oral; D005744:Gastric Acid / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006801:Humans; D008954:Models, Biological; D011899:Ranitidine / Q000493:pharmacokinetics* / Q000494:pharmacology*
D006635:Histamine H2 Antagonists; D011899:Ranitidine